Umut Eser

co-founder & AI @weave_bio
[email protected]

[Umut Eser @Umut1Eser]

The new platform we have been working on, @weave_bio, is partially out of stealth. Stay tuned for exciting updates:

https://t.co/yfWVl2y9yO

[Umut Eser @Umut1Eser]

@Yesterday_work_ Only the 14th author is somewhat affiliated with NVIDIA and the whole paper becomes “NVIDIA paper”.

[Weave Bio @weave_bio]

⏱️ When Health Authorities have questions, every hour counts.

Meet HAQ Manager, Weave’s new AI-native solution that automates and accelerates Health Authority Question responses — built with Takeda.

🔗 Read more: https://t.co/xAjdXn1MUm
🎥 Register for the live demo (Nov 14): https://t.co/ZYRi9MpizU

#WeaveBio #HAQ #DrugDevelopment #RegulatoryInnovation
#AIinPharma #Biotech #LifeSciences

[Weave Bio @weave_bio]

⚡ Last week, the FDA took an important step toward transparency.

By publishing the same filing checklists CDER reviewers use internally, the FDA is helping sponsors understand what “complete and reviewable” really means. It’s a practical move that could prevent avoidable Refuse to File (RTF) delays that can cost teams months or even years.

You can read the full announcement here:
👉 https://t.co/NbeRGIevoi

For anyone managing regulatory data, this release underscores what we see every day: clarity and organization aren’t just nice to have, they’re make-or-break.

At Weave, we help teams stay ahead of these moments. Our platform connects data, context, and collaboration so you’re never scrambling to meet the standard—you’re already there.

Learn how we can make your next submission go smoother at https://t.co/r617XEBmtU.

#WeaveBio #FDA #DrugDevelopment #RegulatoryInnovation
#AIinPharma #Biotech #LifeSciences

[Umut Eser @Umut1Eser]

We’re growing.

[Weave Bio @weave_bio]

We build tools that support people. By combining human expertise with intelligent automation, Weave helps regulatory and development teams work smarter, with more accuracy and less busywork. As more companies partner with Weave, our team is growing across product, engineering, AI research, and go-to-market.

Current openings include:
💼 Go-to-Market: Account Executives (Biotech & Enterprise), Principal Customer Success Manager, Product Marketing Manager, Vice President of Sales
⚙️ Engineering: AI Engineering Team Lead, Frontend Engineering Team Lead, Senior/Staff Backend Engineer, Senior/Staff Frontend Engineer
🧩 Product: Senior Product Manager
🧠 Research & Strategy: AI Research Scientist

👉 Visit our careers page to learn more: https://t.co/kTu0FAuk4K

#WeaveBio #Hiring #LifeSciences #DrugDevelopment #AIinHealthcare

[Umut Eser @Umut1Eser]

It’s now official! Excited to announce that we raised $20m Series A.

I can already feel the phase transition from proving the value proposition to scaling and capturing the value creation.

So proud of the team @weave_bio !

[Weave Bio @weave_bio]

In a market flooded with AI buzzwords, Weave is solving one of drug development's most critical bottlenecks: regulatory workflows that determine how quickly life-changing therapies reach patients.

Today, we're proud to announce our $20M Series A, led by @USVP_ , with participation from @iendeavors, @magneticvc, @trailmixvc , @CharacterVC, and Serrado Capital.

This isn't just about technology—it's about impact:
✅ Accelerating regulatory timelines by 50%+
✅ Expanding across the full therapeutic lifecycle (IND to NDA to post-market)
✅ Scaling globally to serve drug developers worldwide

What sets us apart? We're AI-native by design, not by rebranding. Our platform delivers speed, accuracy, and compliance—powered by AI, validated by human expertise.

The future of regulatory workflows is here. And it's built on substance, not hype.

👉Read the full announcement: https://t.co/9WMItP3xA5

#WeaveBio #SeriesA #DrugDevelopment #RegulatoryInnovation #AIinPharma #Biotech #LifeSciences

[Weave Bio @weave_bio]

Exciting news! We're thrilled to announce our strategic partnership with @Parexel !

Parexel brings deep regulatory consulting expertise that enhances our AI solutions, enabling us to expand The Weave Platform across the entire regulatory lifecycle. Together, we’ve already delivered proven results with 50% faster IND authoring timelines, helping sponsors initiate clinical trials sooner while maintaining the highest quality and standards.

Read the full announcement: https://t.co/xEDBzj9MuC

[Umut Eser @Umut1Eser]

LLMs aren’t dumb — they’re unstructured.

Give GPT-4.1-mini a CoT instruction 10-digit multiplication: ❌
Give GPT-4.1-mini an algorithmic scaffold: ✅ 70–100% accuracy.

👉 Prompting = programming.
👉 Structure unlocks hidden capacity.

Full essay here:
https://t.co/93IbpJcE8j

[Umut Eser @Umut1Eser]

LLMs can write poetry but can’t count stripes on a shoe.

Intelligence needs structure, not scale.

I ran an experiment in the most absurd lab: Brainfuck.
Multi-scale solutions emerged!

Full story 👇
https://t.co/YTZpTbniXR

#AI #Emergence #NeuroSymbolic

[Umut Eser @Umut1Eser]

Vision: Add a stripe to Adidas → AI still says “three.”
Math: Add an irrelevant clause → accuracy drops 65%.
Medicine: Replace answer with “None of the above” → collapse.

Pattern ≠ reasoning.

Post + examples → https://t.co/m12DvoFnkW

[Weave Bio @weave_bio]

💬 𝗪𝗲𝗮𝘃𝗲 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆

Your words keep us moving forward. Every time we hear how 𝗧𝗵𝗲 𝗪𝗲𝗮𝘃𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 saves you hours, catches the details you missed,  or helps regulatory writing feel less like a bottleneck — we listen. And we build.

This feedback doesn’t just make us smile (although it does) — it shapes our roadmap. It’s the reason we keep pushing to make The Weave Platform faster, smarter, and even more helpful for biotech and pharma teams.

Your feedback isn’t just heard — it’s built into the future of The Weave Platform. 🚀

#WeaveWednesday #CustomerFeedback #Biotech #Pharma #RegulatoryWriting #ProductInnovation

[Umut Eser @Umut1Eser]

After getting many positive feedback, I decided to write the webinar content as a Substack post:

https://t.co/NRFbo86fMn

Audience: non-developers

I might write something more technical laying out the emerging best practices across domains that I have seen so far in the future.

[Weave Bio @weave_bio]

🫶 🫶 Our customers are the reason Weave exists — and the reason we keep raising the bar.

Whether they’re leading small but mighty teams in early-stage biotech or driving regulatory execution in later-phase clinical programs, they share one thing: They’re focused on the science — and they don’t have time for inefficient workflows.

We built Weave to give them the space to focus on what matters most — not stitching together content by hand, and not managing formatting and version chaos.

We’re proud to support the people who push science forward — and inspired by the work they do every day.

These logos represent just a handful of the forward-thinking teams using Weave. We encourage you to check out their work — and imagine what’s possible. 🫶

#WeaveWednesday #SubmissionReady #BiotechOps #PoweredByOurPartners

[Umut Eser @Umut1Eser]

RT @weave_bio: Sneak Peek Alert: AutoCT at SCT 2025

Headed to Vancouver for the @SCTorg Society for Clinical Trials meeting on May 19–20?…

[Steve Jurvetson @FutureJurvetson]

Super Founders 📕 summary
If a founder has prior experience of being a successful founder, their next startup has an 8x higher chance of becoming a unicorn. “This was the strongest difference I observed in my data between the billion-dollar and the random group.” — author Ali Tamaseb

“Almost all the founders of billion-dollar companies are builders. Going back to high school, or even younger, many of them started side projects, student clubs, or even companies. Those projects weren’t about striking it rich so much as scratching an itch to create.”

Study period: 2005 – 2018, 200 unicorns vs a random sample of 200 non-unicorns that also raised at least $3M of VC. It’s “one of the largest data sets ever compiled on startups and what leads to their success.”

“Over 90% of billion-dollar startups were VC backed.” Co-investment with a top tier VC -> 5x the outcome.

"Some of the largest companies in my study were founded during the recession. Perhaps innovation comes from constraints.”

“Unicorns make up less than 0.1% of startups.”

“Just over half of the unicorns were headquartered in the SF Bay Area, compared to 1/3 in the random group.”

Not correlated with success: age of founders, number of founders, or domain expertise. "The mythology doesn't always match reality."

“Fewer then 50% of founding CEOs had much, if any, work experience related to their startup. In science-related startups, the story is a little different. 75% of founders in biotech had direct relevant experience, enterprise tech 40%, and in consumer only 30% had direct relevant experience.”

“The founders of billion-dollar companies were more likely to work for themselves or to have worked at a tier-one company.”

“If there is one takeaway from this book, the best preparation for starting a wildly successful company is starting a company. If you have never started a company, the best preparation is to start something, maybe a club or a side hustle.”

Unicorn founders “tend to have a compulsion to build stuff.”

[Umut Eser @Umut1Eser]

If you are developing an SDK, create a button for exporting documentation for people to provide context to their favorite smart-IDEs or AI Assistant apps like ChatGPT or Claude.

Maybe Cursor/Windsurf/Augment etc. already lets us to set the API doc sites to pull in?

[Jack Morris @jxmnop]

i was surprised to learn how much of modern AI was developed by physicists:

- scaling laws
- alphafold
- RLHF (dario got his phd in biophysics)
- diffusion models
- normalizing flows
- VAEs
- neural tangent kernel
- hopfield networks
- information bottleneck theory
- neural style transfer
- imagenet (apparently feifei has a bachelors in physics)
- chinchilla optimality

[Weave Bio @weave_bio]

✨ #𝗪𝗲𝗮𝘃𝗲𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆 ✨
This week: 𝘁𝗵𝗲 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗗𝗮𝘁𝗮 𝗥𝗼𝗼𝗺 in #AutoIND.

🔍 The Data Room just got a whole lot smarter.

Can’t find that one study? Need to answer Health Authority questions—fast? With the Enhanced Data Room, AutoIND now gives you a whole new way to interact with your data:

📁 Upload smarter
  • Drag and drop full folders directly into the Data Room
  • All PDFs and subfolders upload automatically—structure preserved
  • Batch upload multiple folders and files with no extra manual work

🔎 Search better
  • Keyword search across names, tags, and metadata
  • Deep search uses AI to understand intent—not just words
  • Instantly preview results, auto-scrolled to the relevant page

💬 Ask anything
  • Use the Ask tab (formerly Explore) to query your files
  • Save, rename, and revisit your questions
  • Get draft responses with direct references and downloadable sources

#WeaveBio #AutoIND #WeaveWednesday #DataRoom #RegulatoryTech #AIinBiotech

[Weave Bio @weave_bio]

Blistering speed, real rigor. With a Top 20 Pharma partner, we used AI to draft 94 study summaries across 2 INDs. Avg time: 3.1 hrs vs. 100+ hrs manually (33x faster). Faithfulness: 96%. Quality: 74% on first draft. Evaluation? Still best done by expert humans. 👉 https://t.co/r617XEBUjs

#WeaveBio #AIinPharma #RegulatoryWriting #Biotech #PharmaTech

[Weave Bio @weave_bio]

🚀 Master the Art of Prompting for Regulatory, Clinical, and Corporate Excellence

Missed our live session? The recording is now available!

Learn how to unlock the full potential of AI in your day-to-day workflows—from submission drafting to executive decision-making—with practical, real-world prompting strategies.

🔍 What You’ll Learn:
✨ Anatomy of an Effective Prompt
✨ Advanced Prompting Techniques
✨ Regulatory & Corporate Use Cases
✨ Shaping the Future of AI Interaction

📽️ Access the recording here: https://t.co/TZ1ZfXwGMN

The future belongs to those who know how to talk to AI. Start mastering it today.

#AIinRegulatory #ClinicalTrials #PromptEngineering #RegulatoryAffairs #AIProductivity #DrugDevelopment #MedicalWriting #ClinicalOperations #FutureofWork

[Umut Eser @Umut1Eser]

Many people asked to re-watch the recording of art of promoting webinar.

Some say there were unique insights hard to find online.

So, I uploaded a bit shortened version of it to YouTube.

It’s the very first YouTube video of my channel:

https://t.co/Hze3RHs4t6